Sugi Predict

Sugi Predict / Targets / CACNB2

CACNB2

Voltage-dependent L-type calcium channel subunit beta-2 · Q08289 · CACNB2 on Sugi Atlas →

6,852 patent compounds predicted against CACNB2, 2,942 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL2585915 SCHEMBL2585915 0.51 8/20
SCHEMBL3354274 SCHEMBL3354274 0.62 7/20
SCHEMBL3357851 SCHEMBL3357851 0.54 7/20
SCHEMBL4750473 SCHEMBL4750473 0.52 7/20
SCHEMBL3350921 SCHEMBL3350921 0.49 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL5428566 SCHEMBL5428566 0.52 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL4405461 SCHEMBL4405461 0.55 5/20
SCHEMBL4399845 SCHEMBL4399845 0.54 5/20
SCHEMBL4967687 SCHEMBL4967687 0.51 5/20
SCHEMBL1810921 SCHEMBL1810921 0.51 5/20
SCHEMBL4399843 SCHEMBL4399843 0.50 5/20
SCHEMBL3477582 SCHEMBL3477582 0.47 5/20
SCHEMBL3353571 SCHEMBL3353571 0.47 5/20
SCHEMBL3248439 SCHEMBL3248439 0.45 5/20

Clinical trials — most relevant to CACNB2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis PHASE2COMPLETED
The Response To Ajmaline Provocation in Healthy Subjects PHASE2UNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
International CRDS Registry nanRECRUITING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Verapamil in Supraclavicular Brachial Plexus Block nanUNKNOWN
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants nanRECRUITING
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism nanCOMPLETED
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
Comparison of the Effects of Dexmedetomidine and Lidocaine on Blood Pressure and Heart Rate Response nanCOMPLETED
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
iCorMicA - Stratified Medicine in Angina nanRECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
Painful Channelopathies Study nanUNKNOWN
A Natural History Study of RYR1-Related Disorders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CACNB2 binder may also engage these)

ProteinNameSimilarity
Q8VGC3 — 1.000 Q8VGC3 →
Q8CC27 — 1.000 Q8CC27 →
P54288 — 0.996 P54288 →
Q9MZL5 — 0.995 Q9MZL5 →
Q9MZL7 — 0.986 Q9MZL7 →
CACNB1 Voltage-dependent L-type calcium channel subu 0.984 landscape →
Q8R3Z5 — 0.982 Q8R3Z5 →
P54283 — 0.978 P54283 →
P19517 — 0.973 P19517 →
P54286 — 0.968 P54286 →
P54287 — 0.968 P54287 →
Q90ZY6 — 0.964 Q90ZY6 →
Q9MZL3 — 0.964 Q9MZL3 →
CACNB3 Voltage-dependent L-type calcium channel subunit beta-3 0.964 landscape →
P54285 — 0.963 P54285 →
Q9Z1T4 — 0.963 Q9Z1T4 →
Q5PYH7 — 0.963 Q5PYH7 →
Q8WXI2 — 0.963 Q8WXI2 →
Q9ERG2 — 0.962 Q9ERG2 →
Q6P9S0 — 0.962 Q6P9S0 →
TLK2 Serine/threonine-protein kinase tousled-like 2 0.961 landscape →
Q1ECX4 — 0.961 Q1ECX4 →
Q9BTC8 — 0.961 Q9BTC8 →
Q80YA9 — 0.960 Q80YA9 →
TLK1 Serine/threonine-protein kinase tousled-like 1 0.959 landscape →
P30999 — 0.959 P30999 →
Q5PYH6 — 0.959 Q5PYH6 →
Q62696 — 0.959 Q62696 →
Q8BIE6 — 0.959 Q8BIE6 →
CTNND1 Catenin delta-1 0.959 landscape →